Skip to main content

Epidermolysis Bullosa (EB)

4
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Paradigm Therapeutics
Paradigm TherapeuticsSC - Mount Pleasant
2 programs
2
SD-101 Dermal CreamPhase 31 trial
SD-101 Dermal CreamPhase 31 trial
Active Trials
NCT07482813Not Yet Recruiting80Est. Aug 2027
NCT07482787Not Yet Recruiting80Est. Jun 2027
Xinnate
XinnateSweden - Lund
1 program
1
TCP-25 gelPhase 21 trial
Active Trials
NCT06594393Recruiting32Est. Jun 2027
Castle Creek Biosciences
1 program
1
Diacerein 1% OintmentPhase 11 trial
Active Trials
NCT03472287Completed11Est. Feb 2019
argenx
argenxBelgium - Zwijnaarde
1 program
EfgartigimodPHASE_1_21 trial
Active Trials
NCT07011589Not Yet Recruiting18Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Paradigm TherapeuticsSD-101 Dermal Cream
Paradigm TherapeuticsSD-101 Dermal Cream
XinnateTCP-25 gel
argenxEfgartigimod
Castle Creek BiosciencesDiacerein 1% Ointment

Clinical Trials (5)

Total enrollment: 221 patients across 5 trials

NCT07482813Paradigm TherapeuticsSD-101 Dermal Cream

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Start: Jul 2026Est. completion: Aug 202780 patients
Phase 3Not Yet Recruiting
NCT07482787Paradigm TherapeuticsSD-101 Dermal Cream

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Start: May 2026Est. completion: Jun 202780 patients
Phase 3Not Yet Recruiting
NCT06594393XinnateTCP-25 gel

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Start: Jan 2026Est. completion: Jun 202732 patients
Phase 2Recruiting
NCT07011589argenxEfgartigimod

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Start: Jul 2025Est. completion: Oct 202618 patients
Phase 1/2Not Yet Recruiting
NCT03472287Castle Creek BiosciencesDiacerein 1% Ointment

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Start: May 2018Est. completion: Feb 201911 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 221 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.